5:23 PM
 | 
Jul 20, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA to discuss Xeljanz sNDAs in psoriatic arthritis, accepts UC sNDA

FDA’s Arthritis Advisory Committee will meet on Aug. 3 to discuss sNDAs from Pfizer Inc. (NYSE:PFE) for Xeljanz (Jaquinus) tofacitinib and Xeljanz XR extended release to treat adults with active...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >